ScreenerHero

KRYS Krystal Biotech, Inc.

NAS · US · Healthcare · Biotechnology · krystalbio.com
334.85USD+3.90%Mkt Cap: 9.91B $P/E: 41.96

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company c…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.54BUSDP/E 29.3
MRNA
Moderna, Inc.
$81.13BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$74.79BUSDP/E 18.0
ARGX
argenx SE
$57.11BUSDP/E 34.8
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc.
$44.51BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
ONC
BeOne Medicines AG
$41.14BUSDP/E 64.7
RPRX
Royalty Pharma plc
$32.74BUSDP/E 30.1
ALNY
Alnylam Pharmaceuticals, Inc.
$29.42BUSDP/E 37.1
ROIV
Roivant Sciences Ltd.
$25.84BUSD
BNTX
BioNTech SE
$24.53BUSD
GMAB
Genmab A/S
$24.01BUSDP/E 30.3
INCY
Incyte Corporation
$23.13BUSDP/E 14.5
INSM
Insmed Incorporated
$22.67BUSD
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
JAZZ
Jazz Pharmaceuticals plc
$15.32BUSDP/E 16.2
ASND
Ascendis Pharma A/S
$15.01BUSDP/E 17.5
EXEL
Exelixis, Inc.
$14.58BUSDP/E 18.6
SMMT
Summit Therapeutics Inc.
$13.78BUSD

Key Statistics

Company
Market Cap9.91B USD
Enterprise Value8.70B USD
Revenue (TTM)440.48M USD
Gross Profit366.08M USD
Net Income (TTM)204.83M USD
Revenue/Share15.08 USD
Last Price334.85 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees295
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)41.96
P/E (Forward)34.58
PEG—
EV/EBITDA43.67
EV/Revenue19.76
P/S21.66
P/B7.02
EPS (TTM)7.98
EPS (Forward)9.32
52W Range
158.0879% of range382.54
52W High382.54 USD
52W Low158.08 USD
Profitability
Gross Margin94.08%
Oper. Margin49.00%
EBITDA Margin45.24%
Profit Margin52.64%
ROE16.80%
ROA15.36%
Growth
Revenue Growth24.10%
Earnings Growth38.80%
Cash Flow & Leverage
Operating CF200.87M USD
CapEx (TTM)11.95M USD
FCF Margin34.45%
FCF Yield1.53%
Net Debt-836.78M USD
Net Debt/EBITDA-4.20
Balance Sheet
Debt/Equity0.01
Current Ratio8.32
Quick Ratio7.73
Book Value/Sh45.92 USD
Cash/Share28.57 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)392.11 USD
Upside (mean)+17.1%
Target Range284.00 USD – 474.00 USD
284.00+17.1% to mean474.00
# Analysts9
Ownership
Shares Out.29.60M
Float23.62M
Insiders10.66%
Institutions102.51%
Short Interest
Short Ratio13.7d
Short % Float17.50%
Short % Out.10.69%
Shares Short3.16M
Short (prev mo.)3.20M
Technical
SMA 50342.43 (-2.2%)
SMA 200301.37 (+11.1%)
Beta0.54
S&P 52W Chg14.58%
Avg Vol (30d)270.30K
Avg Vol (10d)256.75K
Technical Indicators
RSI (14)46.9
MACD-3.9725
MACD Signal-2.1149
MACD Hist.-1.8576
BB Upper364.46 USD
BB Middle341.97 USD
BB Lower319.48 USD
BB Width13.15%
ATR (14)11.56 USD
Vol Ratio (20d)1.16x